Q&A with Tony MacDonald, Spectrum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Tony MacDonald, Spectrum
A Q&A with Spectrum Laboratories President Tony MacDonald.

Pharmaceutical Technology
Volume 35, Issue 1, pp. 89



Q&A with
Tony MacDonald, president of Spectrum Laboratories

PharmTech:
What is the biggest industry challenge you're now facing?

MacDonald:
The biggest industry challenge that we see is reducing the cost of single-use technology. Making the technology more affordable would broaden accessibility to the rapid scale-up of vaccine production and help avoid batch-to-batch contamination.

PharmTech:

How do you stay abreast of new developments in the industry?

MacDonald:
Spectrum Laboratories stays abreast of new developments in the pharmaceutical, biopharmaceutical, and biotech markets by maintaining direct contact with end users through our direct sales and marketing team and our distribution partners across the globe. We also attend industry conferences and seminars frequently.

PharmTech:
Do you see a new industry trend emerging?

MacDonald:
The industry trend that is emerging is the replacement of processing equipment that entails a large capital expense, such as stainless-steel vessels, with low-cost and adaptable single-use flow paths. More and more single-use processing components are becoming available, thus increasing the amount of production-scale manufacturing that relies on single-use technology.

PharmTech:
What is the most common demand your clients are currently making of you?

MacDonald:
The most common demands from our customers are traceability of raw materials and materials that are free of animal byproducts.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here